- Home
- CMND vs BDRX Comparison
CMND vs BDRX Comparison
Compare CMND & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMND
- BDRX
- Stock Information
- Founded
- CMND 2017
- BDRX 2000
- Country
- CMND Canada
- BDRX United Kingdom
- Employees
- CMND N/A
- BDRX 13
- Industry
- CMND Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- CMND Health Care
- BDRX Health Care
- Exchange
- CMND Nasdaq
- BDRX Nasdaq
- Market Cap
- CMND 5.3M
- BDRX 4.6M
- IPO Year
- CMND N/A
- BDRX N/A
- Fundamental
- Price
- CMND $1.00
- BDRX $7.54
- Analyst Decision
- CMND
- BDRX
- Analyst Count
- CMND 0
- BDRX 0
- Target Price
- CMND N/A
- BDRX N/A
- AVG Volume (30 Days)
- CMND 97.2K
- BDRX 353.2K
- Earning Date
- CMND 09-11-2025
- BDRX 09-12-2025
- Dividend Yield
- CMND N/A
- BDRX N/A
- EPS Growth
- CMND N/A
- BDRX N/A
- EPS
- CMND N/A
- BDRX N/A
- Revenue
- CMND N/A
- BDRX N/A
- Revenue This Year
- CMND N/A
- BDRX N/A
- Revenue Next Year
- CMND N/A
- BDRX N/A
- P/E Ratio
- CMND N/A
- BDRX N/A
- Revenue Growth
- CMND N/A
- BDRX N/A
- 52 Week Low
- CMND $0.80
- BDRX $5.00
- 52 Week High
- CMND $2.18
- BDRX $92.00
- Technical
- Relative Strength Index (RSI)
- CMND 49.92
- BDRX 51.93
- Support Level
- CMND $0.96
- BDRX $6.60
- Resistance Level
- CMND $1.08
- BDRX $7.84
- Average True Range (ATR)
- CMND 0.05
- BDRX 0.88
- MACD
- CMND 0.00
- BDRX -0.15
- Stochastic Oscillator
- CMND 49.78
- BDRX 17.80
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.